[ET Net News Agency, 4 January 2022] Ascletis Pharma Inc. (01672) announced the
completion of the U.S. Phase I trial of ASC43F, an in-house developed, first-in-class dual
targeting fixed-dose combination (FDC) tablet for non-alcoholic steatohepatitis (NASH).
ASC43F is a drug candidate of Gannex Pharma Co., Ltd. (Gannex), a wholly-owned
subsidiary of the company. (RC)